A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. [electronic resource]
Producer: 20120920Description: 1175-83 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzenesulfonates -- administration & dosage
- Cyclooxygenase 2 -- genetics
- Cytidine Deaminase
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Niacinamide -- analogs & derivatives
- Nucleoside Deaminases -- genetics
- Pancreatic Neoplasms -- drug therapy
- Phenylurea Compounds
- Polymorphism, Single Nucleotide
- Pyridines -- administration & dosage
- Ribonucleoside Diphosphate Reductase
- Sorafenib
- Tumor Suppressor Proteins -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.